Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 413197104 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Vanguard Portfolio Management LLC 13G | 5.1% |
7/31/2026
Event 6/30/2026
|
|
| BlackRock, Inc. 13G/A Amendment 6 | 11.3% |
7/28/2026
Event 6/30/2026
|
|
| Vanguard Group Inc 13G/A Amendment 3 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
FMR LLC
13G/A
Amendment 7
|
5.4% |
2/5/2026
Event 12/31/2025
|
|
| FMR LLC | 5.4% | ||
| Abigail P. Johnson | 5.4% | ||
|
Valor IV Pharma Holdings, LLC
13G/A
Amendment 5
|
3.2% |
11/14/2025
Event 9/30/2025
|
|
| Valor IV Pharma Holdings, LLC | 0% | ||
| Valor Equity Partners IV L.P. | 1.3% | ||
| Valor Equity Partners IV-A L.P. | 0% | ||
| Valor Equity Partners IV-B L.P. | 0.7% | ||
| Valor Equity Associates IV L.P. | 2.2% | ||
| Valor Equity Capital IV LLC | 2.2% | ||
| Valor Management L.P. | 2.2% | ||
| Antonio J. Gracias | 3.2% | ||
| Juan A. Sabater | 2.4% | ||
|
FMR LLC
13G/A
Amendment 6
|
6.7% |
11/5/2025
Event 9/30/2025
|
|
| FMR LLC | 6.7% | ||
| Abigail P. Johnson | 6.7% | ||
| BlackRock, Inc. 13G/A Amendment 5 | 10.1% |
4/29/2025
Event 3/31/2025
|
|
|
Valor IV Pharma Holdings, LLC
13G/A
Amendment 4
|
11.7% |
2/12/2025
Event 12/31/2024
|
|
| Valor IV Pharma Holdings, LLC | 11.6% | ||
| Valor Equity Partners IV L.P. | 9.0% | ||
| Valor Equity Partners IV-A L.P. | 0.5% | ||
| Valor Equity Partners IV-B L.P. | 2.1% | ||
| Valor Equity Associates IV L.P. | 11.6% | ||
| Valor Equity Capital IV LLC | 11.6% | ||
| Valor Management L.P. | 11.6% | ||
| Antonio J. Gracias | 11.7% | ||
| Juan A. Sabater | 11.6% | ||
| Marshman Fund Trust II 13G/A Amendment 1 | 10.6% |
2/10/2025
Event 12/31/2024
|
|
| BlackRock, Inc. 13G/A Amendment 4 | 12.2% |
2/5/2025
Event 12/31/2024
|
|
| Vanguard Group Inc 13G/A Amendment 2 | 8.3% |
1/30/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 18 | 426 k | $8.17 M |
| 2026 Q2 | 338 | 56.2 M | $2.02 B |
| 2026 Q1 | 322 | 56.0 M | $1.56 B |
| 2025 Q4 | 336 | 50.1 M | $1.88 B |
| 2025 Q3 | 315 | 47.6 M | $1.31 B |
| 2025 Q2 | 289 | 51.5 M | $1.63 B |
| 2025 Q1 | 284 | 50.3 M | $1.67 B |
| 2024 Q4 | 255 | 52.8 M | $1.82 B |
| 2024 Q3 | 244 | 50.4 M | $2.01 B |
| 2024 Q2 | 232 | 51.2 M | $1.54 B |
| 2024 Q1 | 218 | 50.8 M | $1.71 B |
| 2023 Q4 | 233 | 49.4 M | $1.59 B |
| 2023 Q3 | 218 | 49.6 M | $1.62 B |
| 2023 Q2 | 223 | 52.0 M | $1.83 B |
| 2023 Q1 | 230 | 51.5 M | $1.68 B |
| 2022 Q4 | 256 | 52.5 M | $2.87 B |
| 2022 Q3 | 213 | 52.2 M | $2.31 B |
| 2022 Q2 | 190 | 48.1 M | $2.39 B |
| 2022 Q1 | 188 | 46.1 M | $2.26 B |
| 2021 Q4 | 151 | 44.8 M | $1.91 B |
| 2021 Q3 | 103 | 30.9 M | $1.19 B |
| 2021 Q2 | 86 | 28.5 M | $804 M |
| 2021 Q1 | 59 | 27.8 M | $918 M |
| 2020 Q4 | 60 | 28.0 M | $998 M |
| 2020 Q3 | 45 | 28.5 M | $941 M |